Who Paid My Doc
Precedex
Drug Sedative
NDC 0409-1638-02
General payments
$123,521
Research payments
$1,648,200
Through program year 2025, $123,521 in general payments and $1,648,200 in research payments were reported against Precedex (Sedative).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
13 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $7,700 | 3 |
| 2025 | Research | $3,080 | 3 |
| 2024 | General | $1,000 | 1 |
| 2024 | Research | $660 | 2 |
| 2023 | Research | $10,248 | 5 |
| 2022 | General | $1,725 | 2 |
| 2022 | Research | $197,435 | 39 |
| 2021 | General | $49,960 | 15 |
| 2021 | Research | $1,141,069 | 186 |
| 2020 | General | $40,873 | 85 |
| 2020 | Research | $285,667 | 58 |
| 2019 | General | $22,264 | 28 |
| 2019 | Research | $10,042 | 3 |
Breakdown
Each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
134 general · 296 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.